AstraZeneca Announces Major Organizational Restructuring with Launch of New CCiC Innovation Management Team

Recently, AstraZeneca announced the latest organizational restructuring and the establishment of a new CCiC Innovation Management Team, which will be officially implemented on July 1. The specific personnel appointments are as follows:

The original innovative market positions of each business unit will be officially transferred to the CCIC Innovative Disease Management Team under the Digital and Commercial Innovation Department, forming a commercial innovation team based on therapeutic areas and comprehensive channels. This team will be led by Ms. Lily Zhu, Vice President of AstraZeneca China, who is also the head of the Digital and Commercial Innovation Department and the Commercial Strategy and Operational Excellence Department.

At the same time, officially appointed:

Mr. Wang Jian serves as the Executive Director of Commercial Innovation for Cardiovascular, Renal, and Metabolic fields, leading his team to continue supporting the model upgrade, implementation, and daily management of MMC, exploring the commercial insurance service package model in the CVRM field, and further promoting the commercial application of the integrated diagnostic and treatment solution for the three highs.

Ms. Cai Xiaoyu serves as the Deputy Director of Commercial Innovation in Respiratory, Digestive, and Autoimmune fields, leading her team to explore business model innovations in the areas of respiratory and digestive immunity. She focuses on the CWMC hospital model, out-of-hospital cough and asthma disease management models with pilot programs, top-level design for the capability building of respiratory disciplines, and is also responsible for the innovative design of integrated Traditional Chinese and Western Medicine.

Mr. Chen Xu, Director of Omni-Channel Commercial Innovation, leads his team to support the implementation of model hospitals for chronic disease management centers at the county level under the Medical Consortium. He also refines the ICDMC grassroots innovation project and supports its successful implementation in community hospitals with the cooperation of local Health Commissions across China. Meanwhile, by promoting smart pharmacies, he explores business model innovations in retail channels.

The incoming Director of Oncology Commercial Innovation will lead the team to support the development of innovative products and models in five major tumor fields: prostate cancer, breast cancer, hematological tumors, lung cancer, and liver cancer, and assist in establishing a closed-loop patient disease management model.